Patents by Inventor Daniel Jon Sall

Daniel Jon Sall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20230234960
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Application
    Filed: March 15, 2023
    Publication date: July 27, 2023
    Inventors: Jolie Anne BASTIAN, Jeffrey Daniel COHEN, Almudena RUBIO, Daniel Jon SALL, Jennifer Anne MCMAHON
  • Selective estrogen receptor degraders
    Patent number: 11634426
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: April 25, 2023
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall, Jennifer Anne McMahon
  • Methods of treating cancer using a combination of SERD Dosing Regimens
    Publication number: 20220288019
    Abstract: Disclosed herein are dosing regimens for the administration of a compound of Formula I: or pharmaceutically acceptable salt thereof to patients in need of such treatment. The dosing regimens include adjuvant therapy.
    Type: Application
    Filed: March 8, 2022
    Publication date: September 15, 2022
    Inventors: Shripad Venkatraman BHAGWAT, Lillian Mary SMYTH, Suzanne Rebecca Lou YOUNG, Natalie Starr HOLMAN, Daniel Jon SALL, Safi SHAHDA, Eunice Soek Mun YUEN
  • SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20210403480
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Application
    Filed: September 2, 2021
    Publication date: December 30, 2021
    Inventors: Jolie Anne BASTIAN, Jeffrey Daniel COHEN, Almudena RUBIO, Daniel Jon SALL, Jennifer Anne MCMAHON
  • Selective estrogen receptor degraders
    Patent number: 11117902
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: September 14, 2021
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall, Jennifer Anne McMahon
  • SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20210260052
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts, pharmaceutical compositions, uses, and methods of use thereof are provided.
    Type: Application
    Filed: July 11, 2019
    Publication date: August 26, 2021
    Inventors: Jeffrey Daniel COHEN, Daniel Jon SALL
  • SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20200347073
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Application
    Filed: May 18, 2020
    Publication date: November 5, 2020
    Inventors: Jolie Anne BASTIAN, Jeffrey Daniel COHEN, Almudena RUBIO, Daniel Jon SALL
  • 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer
    Patent number: 10759786
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: September 1, 2020
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • Selective estrogen receptor degraders
    Patent number: 10654866
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: May 19, 2020
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall
  • SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20200017516
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Application
    Filed: July 11, 2019
    Publication date: January 16, 2020
    Inventors: Jolie Anne BASTIAN, Jeffrey Daniel COHEN, Almudena RUBIO, Daniel Jon SALL
  • Pyrazolylaminobenzimidazole derivatives as JAK inhibitors
    Patent number: 10344018
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 9, 2019
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, Daniel Jon Sall
  • Pyrazolylaminobenzimidazole derivatives as JAK inhibitors
    Patent number: 10323019
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: June 18, 2019
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, David Andrew Coates, Daniel Jon Sall, Timothy Andrew Woods
  • PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20190177300
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Application
    Filed: February 12, 2019
    Publication date: June 13, 2019
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, David Andrew Coates, Daniel Jon Sall, Timothy Andrew Woods
  • 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER
    Publication number: 20190161477
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Application
    Filed: May 31, 2017
    Publication date: May 30, 2019
    Inventors: Jolie Anne BASTIAN, Jiehao CHEN, Jeffrey Daniel COHEN, James Robert HENRY, William Thomas MCMILLEN, Bradley Earl REAMAN, Almudena RUBIO, Daniel Jon SALL, Gaiying ZHAO
  • PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20180325873
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Application
    Filed: July 10, 2017
    Publication date: November 15, 2018
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, David Andrew Coates, Daniel Jon Sall, Timothy Andrew Woods
  • 2,3-dihydro-1H-indole compounds
    Patent number: 9872853
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: January 23, 2018
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • 2,3-DIHYDRO-1H-INDOLE COMPOUNDS
    Publication number: 20170354641
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Application
    Filed: May 31, 2017
    Publication date: December 14, 2017
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • Tetrasubstituted pyridazine hedgehog pathway antagonists
    Patent number: 8507490
    Abstract: The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C—R1 or N; R1 is hydrogen, fluoro or cyano; R2 is formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; R3 is methyl or trifluoromethyl; R4 is pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino; R5 is trifluoromethyl or methylsulfonyl; R6 is hydrogen or methyl; and R7, R8, R9, R10 and R11 are independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that at least two of R7, R8, R9, R10 and R11 are hydrogen useful in the treatment of cancer.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: August 13, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Julia Marie Clay, Jeffrey Daniel Cohen, Philip Arthur Hipskind, Karen Lynn Lobb, Daniel Jon Sall, Michelle Lee Thompson, Takako Wilson (nee Takakuwa)
  • Tetrasubstituted pyridazines hedgehog pathway antagonists
    Patent number: 8445493
    Abstract: The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: May 21, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Julia Marie Clay, Takako Wilson (nee Takakuwa), Michelle Lee Thompson, Daniel Jon Sall, Philip Arthur Hipskind
  • Disubstituted phthalazine hedgehog pathway antagonists
    Patent number: 8404687
    Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: March 26, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Philip Arthur Hipskind, Daniel Jon Sall, Takako Wilson (nee Takakuwa)